title: [Immunosuppressives to prevent rejection reactions after allogeneic corneal transplantation].
abstract: In order to prevent rejection of an allogeneic corneal transplant after perforating (high risk) keratoplasty, active agents from different classes of pharmacological substances are used, as with solid organ transplantation. In addition to glucocorticoids, antiproliferative agents, small molecule inhibitors and antibodies, those belonging to the group of macrolides with their many derivatives represent an interesting class of substances in this context. As a supplement to cyclosporin A (CSA) the most successful macrolide in transplantation medicine, animal experiments are currently being carried out to test newer macrolide derivatives, such as sanglifehrin A (SFA). This overview describes the classes of drugs and modes of action of currently administered standard medications in the clinical routine and new developments are presented.
authors.affiliation: Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Killianstr. 5, 79106, Freiburg im Breisgau, Deutschland, Thabo.Lapp@uniklinik-freiburg.de.
authors.forename: T
authors.initials: T
authors.lastname: Lapp
authors.forename: P
authors.initials: P
authors.lastname: Maier
authors.forename: F
authors.initials: F
authors.lastname: Birnbaum
authors.forename: G
authors.initials: G
authors.lastname: Schlunck
authors.forename: T
authors.initials: T
authors.lastname: Reinhard
mesh_terms: D016039:Corneal Transplantation / Q000009:adverse effects*; D006084:Graft Rejection / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007634:Keratitis / Q000209:etiology / Q000517:prevention & control*; D011292:Premedication / Q000379:methods*; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D007166:Immunosuppressive Agents